Pasithea Therapeutics (KTTA) Interest Expenses (2020 - 2026)

Pasithea Therapeutics has reported Interest Expenses for 7 years, with the latest figure at $630164.0 in Q1 2026.

• Quarterly Interest Expenses fell 50.0% year-over-year to $630164.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $630164.0 (down 50.0% YoY) and the FY2025 annual result came in at $882.4 million, up 2005245.45% from the prior year.
• Interest Expenses climbed to $630164.0 in Q1 2026 per KTTA's latest filing, from $77788.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $1.9 million in Q3 2024 and troughed at $15700.0 in Q4 2022.
• A 5-year average of $690468.7 and a median of $630164.0 in 2023 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2024: Interest Expenses sank 98.31% in 2022, then surged 200.0% in 2024.
• Over 5 years, Interest Expenses stood at $15700.0 in 2022, then soared by 3913.78% to $630164.0 in 2023, then soared by 200.0% to $1.9 million in 2024, then slumped by 95.89% to $77788.0 in 2025, then soared by 710.1% to $630164.0 in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $630164.0, $77788.0, and $630164.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.